Relvar Ellipta 100 - 30 doses for inhalation (asthma, bronchitis)

General information on Japanese Relvar Ellipta 30 doses for inhalation

Package details: 30 doses (dosage 100)

Manufacturer: GlaxoSmithKline K.K., Japan

Active ingredient: vilanterol trifenatate (chemical formula C44H49Cl2NO7), fluticasone furoate (chemical formula C27H29F3O6S)

Medical effect: Relvar inhaler contains anti-inflammatory synthetic glucocorticoid and ultra-long-acting β2 adrenoreceptor agonist. It’s effective for preventing attacks and symptoms in patients with bronchial asthma or chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema).

Contraindications and precautions:

Do not use this inhaler to relieve an asthma attack or acute exacerbation of symptom that has already begun. Do not use in patients with infections or deep mycosis. Do not use in pregnant or breastfeeding women.

Dosage and administration of Japanese inhaler Relvar Ellipta 30 doses

Do not shake the inhaler before use. Use the inhaler in the following way:

1. open the cover when ready to inhale,
2. slide the cover down until a click,
3. put the mouthpiece between your lips and inhale,
4. close the inhaler,
5. gargle the throat or rinse out your mouth after inhaling.

Store at the room temperature, but not more than 25C degrees. The dose counter counts down by 1 to confirm.

Use 1 inhalation 1 time a day at the same time each day.

How effective is Relvar Ellipta 30 doses for inhalation from Japan?

Relvar Ellipta inhaler has an anti-inflammatory effect on the airways and a long bronchodilator effect by a beta 2 adrenergic receptor stimulating action. Its construction releases two powder components at the same time without shaking or any other additional action for mixing the components. Vilanterol trifenatate produces a rapid and prolonged effect over 24 hours, helping to relax the muscles of the small air passages in the lungs (R. Kempsford, V. Norris, S. Siederer. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulmonary Pharmacology & Therapeutics, 2013 Apr, 26(2):256-64). By this, Relvar Ellipta inhaler helps to open the airways and makes it easier for air to get in and out of lungs.

Who should use Relvar Ellipta 30 doses for inhalation?

Japanese inhaler Relvar Ellipta 30 doses is effective for preventing attacks and symptoms in patients with bronchial asthma or chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema). It should be used every day and not only when the patient has breathing problems or other symptoms of COPD and asthma. It should not be used to relieve a sudden attack of breathlessness or wheezing.